Zacks highlights Eli Lilly, HSBC, Palantir, and CBL & Associates in latest analyst reports

Industry
โดย Zacks Investment Research·Read original
Summary · why it matters

Zacks Equity Research featured new reports on 16 major stocks, including Eli Lilly, HSBC, Palantir Technologies, and micro-cap CBL & Associates Properties. Eli Lilly shares have gained 58.2% over the past year, driven by strong demand for GLP-1 drugs Mounjaro and Zepbound, while its new oral obesity pill Foundayo is seen as a potential game-changer. HSBC shares rose 69.1%, supported by wealth momentum in Asia and the completed privatization of Hang Seng Bank, though higher expected credit losses and elevated expenses pose headwinds. Palantir shares declined 5.8% amid a broader industry drop of 18%, with its AI platforms driving government and commercial growth, but competition and no dividend remain concerns. CBL & Associates Properties, a micro-cap with a market capitalization of $1.63 billion, surged 119.3%, benefiting from stable operations and capital recycling, though modest organic growth and tenant turnover present risks.

Impact on stocks 4

Biotech & Genomic Medicine▲ · 1 stocks
Eli Lilly and Company
LLY
▲ PositiveDemandrelevance

Strong demand for GLP-1 drugs Mounjaro and Zepbound drove 58.2% share gain.

Real Estate▲ · 1 stocks
Financials▲ · 1 stocks
HSBC Holdings PLC
HSBA
± MixedCapitalrelevance

Wealth momentum in Asia and Hang Seng Bank privatization support, but higher credit losses and expenses are headwinds.

Defense & Geopolitical Fragmentation▲ · 1 stocks
Palantir Technologies Inc.
PLTR
± MixedTechnologyrelevance

AI platforms driving growth but competition and no dividend remain concerns; shares declined 5.8%.

© 2026 MarketDXNews